DFS of Ph+ ALL patients stratified according to MRD levels. (A) DFS at 36 months of patients enrolled in the GIMEMA 0904 trial (imatinib plus steroids) stratified on the basis of a MRD reduction cut-point of 1.3 log at the end of induction (day +50): 26 patients achieved a MRD reduction ≥1.3, whereas 10 did not. Adapted from Chiaretti et al.¹⁶  (B) DFS at 20 months of patients enrolled in the GIMEMA 1205 trial (dasatinib plus steroids) stratified based on a MRD reduction cut-point level of <10⁻³ at the end of induction (day +85): 25 patients achieved BCR-ABL levels <10⁻³ and 23 did not. Adapted from Foà et al.¹⁵